You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Suppliers and packagers for generic pharmaceutical drug: estradiol; levonorgestrel


✉ Email this page to a colleague

« Back to Dashboard


estradiol; levonorgestrel

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Bayer Hlthcare CLIMARA PRO estradiol; levonorgestrel FILM, EXTENDED RELEASE;TRANSDERMAL 021258 NDA Bayer HealthCare Pharmaceuticals Inc. 50419-491-04 4 PATCH in 1 CARTON (50419-491-04) / 7 d in 1 PATCH 2003-11-21
Bayer Hlthcare CLIMARA PRO estradiol; levonorgestrel FILM, EXTENDED RELEASE;TRANSDERMAL 021258 NDA Bayer HealthCare Pharmaceuticals Inc. 50419-491-73 1 PATCH in 1 CARTON (50419-491-73) / 7 d in 1 PATCH 2003-11-21
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drugs: Estradiol and Levonorgestrel

Last updated: July 29, 2025

Introduction

The pharmaceutical landscape for hormone-based medications such as Estradiol and Levonorgestrel is vast and strategic. Both compounds are critical in hormone replacement therapy, contraception, and other clinical applications. Identifying and understanding key suppliers is essential for pharmaceutical companies, healthcare providers, and policymakers aiming for reliable sourcing, regulatory compliance, and cost efficiency. This article provides a comprehensive overview of primary suppliers for Estradiol and Levonorgestrel, emphasizing manufacturing capabilities, geographic distribution, regulatory status, and market dynamics.

Overview of Estradiol and Levonorgestrel

Estradiol, a natural estrogen, is foundational in hormone replacement therapies, managing menopausal symptoms, osteoporosis, and certain hormonal deficiencies. It is available in various formulations, including oral tablets, transdermal patches, and topical gels.

Levonorgestrel is a progestin widely used in contraception, emergency contraception, and hormonal therapies. It is available in intrauterine devices (IUDs), pills, and implants, reflecting diverse administration routes.

Both drugs are included on the World Health Organization's list of essential medicines, underscoring their global importance.

Key Global Suppliers for Estradiol

1. Primary Manufacturing Countries and Companies

  • China
    China leads global production of bulk Estradiol, with several state-of-the-art API (Active Pharmaceutical Ingredient) manufacturers such as Hengyang Guanghua Pharmaceutical Co., North China Pharmaceutical Group Corporation, and Sichuan Huaxi Pharmaceutical. These producers benefit from cost-effective manufacturing, substantial capacity, and detailed regulatory frameworks aligned with local authorities.

  • India
    Indian pharma giants like Sun Pharma, Cadila Healthcare (Zydus), and Lupin are significant suppliers—either through domestic production or contract manufacturing. They adhere to stringent CGMP (Current Good Manufacturing Practices) and export to markets worldwide, including the US, Europe, and emerging economies.

  • European Union & United States
    Although primarily consumers, some European companies such as BASF (Germany) and U.S.-based Pfizer and Teva manufacture high-purity Estradiol APIs. These sources are often used in high-value formulations requiring premium standards.

2. Contract Manufacturers and Exporters

Global pharmaceutical companies frequently collaborate with Contract Manufacturing Organizations (CMOs) in China and India for bulk production. Notable CMOs include BBI Life Sciences (India) and Fosun Pharma (China). These organizations ensure regulatory compliance and scale-up capabilities.

3. Regulatory and Quality Considerations

Suppliers with adherence to stringent standards such as OECD Guidelines, EMA, and FDA approvals ensure API quality and consistent supply. For example, Chinese and Indian manufacturers increasingly seek WHO prequalification to access global markets.

Key Global Suppliers for Levonorgestrel

1. Leading Manufacturers

  • Bayer AG (Germany)
    As the original innovator of levonorgestrel-based contraceptives, Bayer remains a primary supplier of branded and generic formulations globally. Their manufacturing is characterized by high-quality standards and extensive regulatory approvals.

  • Samsung Biologics (South Korea) and LG Chem
    These companies supply Levonorgestrel as APIs and in combination products, leveraging advanced biotechnologies and large-scale manufacturing capabilities.

  • Indian Pharma Companies
    Sun Pharma, Dr. Reddy’s Laboratories, GSK (GSK Global), and Biocon produce Levonorgestrel APIs and finished dosage forms, often at lower costs but with high regulatory compliance.

2. Chinese API Manufacturers

Chinese companies such as Heng Siang Pharmaceutical Group and Zhejiang Hisun Pharmaceutical have established a reputation for producing Levonorgestrel APIs that satisfy international regulatory standards. The increasing quality and quantity of Chinese APIs have expanded their export footprint.

3. Regional Supply Considerations

  • Europe and North America
    These regions predominantly rely on European and North American manufacturers for high-quality Levonorgestrel APIs, especially for regulated markets requiring strict compliance with GMP, EMA, and FDA standards.

  • Emerging Markets
    Indian and Chinese APIs are increasingly prevalent due to cost advantages, with some markets also verifying supplier quality through rigorous regulatory pathways.

Market Dynamics and Supply Chain Considerations

Regulatory Compliance

With increased scrutiny from global regulators, suppliers must ensure APIs meet international standards. The World Health Organization’s prequalification program facilitates global procurement, favoring compliant Chinese and Indian producers.

Supply Chain Resilience

The COVID-19 pandemic exposed vulnerabilities in API supply chains, leading to diversification strategies. Companies now seek multiple sources across geographic regions to mitigate risks associated with geopolitical tensions, regulatory changes, and raw material shortages.

Pricing Trends

Emerging market suppliers offer cost advantages, but premium markets demand high purity, strict validation, and consistent supply, often favoring established European and North American producers.

Conclusion

The supply landscape for Estradiol and Levonorgestrel involves a diverse array of global players, predominantly in China and India, complemented by established European and North American producers. Regulatory adherence, manufacturing quality, and supply stability remain critical for sourcing these hormones effectively. Strategic partnerships, supplier diversification, and compliance with international standards are vital components influencing procurement decisions.

Key Takeaways

  • China and India dominate primary API production for both Estradiol and Levonorgestrel due to cost-effectiveness and capacity.
  • European and North American suppliers primarily handle high-standard formulations, especially for regulated markets.
  • Regulatory compliance (GMP, WHO prequalification, EMA, FDA approval) is crucial for supplier selection.
  • Supply chain resilience has become a priority, prompting diversification and strategic sourcing.
  • Contract manufacturing organizations are integral in scaling production and maintaining quality.

FAQs

1. Which countries are the leading producers of Estradiol APIs globally?
China and India are the primary producers of Estradiol APIs, with Chinese manufacturers supplying a significant proportion due to cost-effectiveness and capacity. European and U.S. companies manufacture high-purity versions mainly for regulated markets.

2. Are Chinese and Indian suppliers compliant with international regulatory standards?
Many Chinese and Indian API manufacturers have achieved WHO prequalification and adhere to GMP standards recognized by EMA and FDA, but due diligence remains essential when sourcing for regulated markets.

3. How does supplier diversification impact the procurement of Levonorgestrel?
Diversification reduces risk by minimizing reliance on a single source or country, ensuring supply continuity amidst geopolitical or regulatory disruptions, and enabling competitive pricing.

4. What role do Contract Manufacturing Organizations play in the supply chain of these hormones?
CMOs facilitate scale-up, ensure regulatory compliance, and provide flexible manufacturing options, especially for generic formulations or custom dosage forms.

5. What are the emerging trends affecting suppliers of Estradiol and Levonorgestrel?
Trends include increased regulatory rigor, push for WHO prequalification, pandemic-induced supply chain reorganization, and technological advancements in API synthesis that improve purity and efficiency.


References

[1] WHO. WHO Model List of Essential Medicines. 2023.
[2] US Food and Drug Administration. API Manufacturer Directory.
[3] European Medicines Agency. GMP and API Regulations.
[4] International Pharmaceutical Regulators Forum. API Quality Standards.
[5] Industry Reports on API Manufacturing Trends.

Note: The above references are representative; actual sourcing data should be verified through current industry databases and regulatory disclosures.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.